Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

87.15EUR
2 Dec 2016
Change (% chg)

€0.37 (+0.43%)
Prev Close
€86.78
Open
€86.55
Day's High
€87.46
Day's Low
€86.03
Volume
2,437,705
Avg. Vol
2,213,950
52-wk High
€125.70
52-wk Low
€83.45

Select another date:

Tue, Nov 22 2016

BRIEF-Monsanto provides update on Bayer merger

* Monsanto co - in connection with merger with Bayer, a purported class action lawsuit, captioned ken gawrych, was filed on nov. 16, 2016

European shares weighed down by weaker banks, Bayer drop

* Hugo Boss slumps as revival plan seen taking time (ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets)Adds detail, closing prices)

BRIEF-Bayer places 4 bln euros of mandatory convertible notes

* Says successfully places EUR 4 billion of mandatory convertible notes

Bayer to raise four billion euros via convertible notes for Monsanto deal

LONDON/BERLIN German chemicals and healthcare group Bayer AG is selling 4 billion euros ($4.3 billion) worth of mandatory convertible notes to help fund its proposed acquisition of U.S. seeds company Monsanto Co .

UPDATE 1-Bayer to raise 4 bln euros via convertible notes for Monsanto deal

* Proceeds will be used for $66 bln Monsanto buy (Adds comment by banker, background)

BRIEF-Germany's Bayer mandatory convertible bond issue covered - source

* 4 billion euro mandatory convertible bond issue covered - source (Reporting by Dasha Afanasieva)

Bayer to issue convertible notes for Monsanto buy

BERLIN, Nov 15 German chemicals and healthcare group Bayer AG will issue 4 billion euros ($4.3 billion) in mandatory convertible notes as part of measures to fund its acquisition of U.S. seeds company Monsanto Co.

BRIEF-Bayer to issue convertible notes for Monsanto buy

* Bayer to issue mandatory convertible notes Source text for Eikon: Further company coverage: (Reporting by Frankfurt Newsroom)

BRIEF-Bayer CEO makes case for U.S.-EU trade after Trump win

Nov 9 Bayer Chief Executive Werner Baumann, commenting on Donald Trump's U.S. presidential election victory:

BRIEF-Bayer comments on the article in "Handelsblatt" on Xarelto

* Believes statements published in 'Handelsblatt' on Nov. 9. about Xarelto are misleading

Select another date: